Alkem Partners with Sonnet for Diabetic Neuropathy Drug in India

Alkem Laboratories Ltd. entered into a licensing agreement with Sonnet BioTherapeutics Holdings. The agreement focuses on developing, manufacturing, and commercializing ‘SON-080’ in India for treating diabetic peripheral neuropathy.

Alkem will conduct clinical trials of ‘SON-080’ in India, with Sonnet’s support for global and local regulatory submissions.

Alkem holds exclusive rights to develop, produce, and market the drug in India. ‘SON-080’ is Sonnet’s proprietary version of “atexakin alfa” and has shown promising results in phase 1b clinical trials.

The drug was well-tolerated, and the trial results suggested potential for rapid improvement in peripheral neuropathy symptoms and long-lasting effects compared to a placebo.

Akhilesh Sharma, Alkem’s President and Chief Medical Officer, highlighted the high prevalence of diabetic peripheral neuropathy in India, making the drug a significant development for the market.

The drug is expected to offer nerve regeneration, potentially modifying the disease in diabetic peripheral neuropathy patients.